Literature DB >> 17366897

[Preparation and identification of human soluble sPD-L1 and its antibodies].

Li-Hui Xu1, Xiao-Yun Chi, Feng-Yao Li, Qian-Tao Jia, Qing-Bing Zha, Xian-Hui He.   

Abstract

This study reports the preparation and identification of soluble programmed death-1 (PD-1) ligand-1 (sPD-L1) and its antibodies of mouse origin. Immobilized metal ion affinity chromatography was used to perform on-column refolding with simultaneous purification of denatured sPD-L1, and soluble sPD-L1 with purity of 95% was obtained. The purified sPD-L1 was verified by immunoblotting using a commercial goat-anti-human PD-L1 antibody. An ELISA-based assay showed that it also had high binding activity for its cognate receptor PD-1. Furthermore, mouse anti-sPD-L1 antiserum of high titer was raised using the purified sPD-L1 as an immunogen, and the specific IgG antibodies were purified using sPD-L1-HiTrap affinity chromatography. In addition, a sensitive sandwich ELISA was established using the purified IgG antibodies together with the commercial goat antibodies. In conclusion, the preparation of soluble sPD-Ll and its antibodies provide the basis for detection of the potential anti-PD-L1 antibodies and soluble PD-L1 in humans as well as for further investigation of its in vivo bioactivities and characterization of its potential receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17366897     DOI: 10.1016/s1872-2075(07)60008-9

Source DB:  PubMed          Journal:  Sheng Wu Gong Cheng Xue Bao        ISSN: 1000-3061


  2 in total

Review 1.  Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Authors:  A Mitsuhashi; Y Okuma
Journal:  Clin Transl Oncol       Date:  2018-01-08       Impact factor: 3.405

2.  High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.

Authors:  Xiaofang Guo; Juan Wang; Jietian Jin; Hao Chen; Zijun Zhen; Wenqi Jiang; Tongyu Lin; Huiqiang Huang; Zhongjun Xia; Xiaofei Sun
Journal:  Transl Oncol       Date:  2018-04-24       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.